I am pleased to lead the continuing evolution of Access Accelerated, a collective effort of the biopharmaceutical and life science industry to pool our resources and work in collaboration with external partners towards a common vision of improved access to #NCD care. Access Accelerated has made unprecedented strides over the past six years, evidenced in our recently published report, "Key lessons in advancing NCD care: Collaboration, Connectivity, Community." Just last year, Access Accelerated supported more than 50 projects in over 30 countries that helped to screen 11 million people and provided life-changing NCD treatment to 3.5 million people - a 1140% increase over the previous year. Collectively, our reach has extended to 700 million people, through training, treatment, and policy shaping. But the most significant impact of our work is the catalytic role that Access Accelerated has played in increasing funding for NCDs. From 2020 to 2022, our initiatives stimulated an additional investment of 3.7 billion USD in NCDs. This remarkable impact underscores the central role of Access Accelerated in unlocking critical investments for NCDs and to the achievement of Universal Health Coverage – a cornerstone of the UN Sustainable Development Goals.

In January 2020 I founded InnAxx Consulting: https://www.innaxxconsulting.comI am pleased to be working with a select group of start-up companies, NGOs, multinational organizations and academic professionals that are bringing truly innovative approaches to improving global health, healthcare delivery, healthy aging and sustainability/ESG. My primary focus is to accelerate human-centric approaches to health and healthcare, new data and technology-based solutions, novel business and financing models, and pragmatic government/regulatory policies that will improve health outcomes for patients suffering from chronic/non-communicable diseases like cancer, cardiovascular disease, diabetes and chronic respiratory illnesses. These diseases represent the world’s leading cause of mortality and disability, and a massive (and growing) economic burden for all countries.

I am pleased to be working as a faculty member and senior advisor to the University of St. Gallen's Executive School of Management, Law and Technology to help them build and launch (in June 2023) a first-in-Europe innovative midlife transition program called NEXT (Networking, Education, eXploration and Transition). The NEXT program helps accomplished professionals at a transitional point in their lives to (1) redefine a meaningful sense of purpose and related activities; (2) build new communities of peers and others; and (3) reassess approaches to health/wellbeing and wealth.

I am fortunate to have been a student of Bill Burnett and Dave Evans, who have successfully taught students at Stanford University and readers of their best-selling book, "Designing Your Life" - that designers don’t analyze, worry, think, or complain; they build their way forward. Now more than ever, we need creative and adaptable tools to cope with the chaos caused by the aftermath of COVID-19. In "Designing Your New Work Life," Burnett and Evans show how design thinking can transform present jobs, and how it can improve experiences of work in times of disruption. Burnett and Evans offer a new concept that makes use of the designer mindsets: Curiosity, Reframing, Radical collaboration, Awareness, Bias to action, and Storytelling. They provide tools, tips, and design ideas for how people can make new possibilities available even when lives have been disrupted, how to enjoy the present moment and how to prototype possible futures.

I thoroughly enjoyed a 16-month fellowship at Stanford's Distinguished Careers Institute (DCI) in Palo Alto, starting in September 2018 and ending in December 2019. The primary focus of my fellowship was on developing new approaches and technologies to enable innovative healthcare delivery models and NCD/chronic disease management initiatives. I worked to identify new solutions and make contacts that bring together (a) experiences in the academic setting including innovation projects underway at Stanford, (b) new technology and data platforms under development in Bay Area companies and global NGOs, and (c) thought leaders around the world who are actively piloting innovative approaches to global health and healthcare delivery. I am proud to have launched a new Stanford Global NCD Innovation Initiative (NCDi), with support from a variety of Stanford centers and professors as well as external partners. I continue to serve as an Ambassador for the Nexel Collaborative, a global alliance of colleges and universities, co-founded by Stanford DCI, with a vision for the future of higher education including midlife transition programs.

Led Amgen's healthcare policy and government affairs activities in regions outside of the United States, focusing on priority issues (HTA/value assessment, price and procurement, and biosimilars), working cross-functionally within Amgen and via industry associations (IFPMA, EFPIA, PhRMA, etc.). Led the development of Amgen's outcomes/value-based healthcare policy work and global health engagement initiative.

Responsible for leading Amgen's global value, access and policy organizations in regions outside the United States. This includes:- Ensuring that Amgen's access, pricing and evidence generation activities in these regions are properly focused and resourced;- Ensuring the development of robust acess plans for each marketed product;- Driving key strategic market access activities impacting Amgen products;- Developing and implementing a public policy/government affairs plan that focuses on key strategic issues (biosimilars, HTA and payment policy, etc.); and- Developing talent and building capabilities in market access and government affairs in the regions and affiliates.

Established successful international external affairs functions (>100 people) for a U.S.-based global leader in medical technology. These include Government Affairs, Reimbursement & Health Economics, Market Development, and Community Affairs/Medtronic Foundation. Responsible for anticipating and responding to the company’s diverse business support needs across multiple jurisdictions, operating both as a member of international management committees and as a leader of global business support functions. Previously built and managed successful Legal/Compliance, PR/Communications and Regulatory Affairs functions (1999-2008). Selected in 2008 to lead a new global strategic initiative focused on integrated market access and healthcare policy initiatives to ensure business success in rapidly-changing healthcare markets.

Managed a team of lawyers, paralegals and outside responsible for all the company's legal work in international markets (outside W. Europe and the United States).